Product Description: Volasertib (BI 6727) is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC50 of 0.87 nM. Volasertib inhibits PLK2 and PLK3 with IC50s of 5 and 56 nM, respectively. Volasertib induces mitotic arrest and apoptosis. Volasertib, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models[1][2].
Applications: Cancer-Kinase/protease
Formula: C34H50N8O3
References: [1]Xie FF, et al. Volasertib suppresses tumor growth in cervical cancer. Am J Cancer Res. 2015 Nov 15;5(12):3548-59./[2]Rudolph D, et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.Clin Cancer Res. 2009 May 1;15(9):3094-102. Epub
CAS Number: 755038-65-4
Molecular Weight: 618.81
Compound Purity: 99.87
Research Area: Cancer
Solubility: DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Apoptosis;Polo-like Kinase (PLK)
Deutsch
English
